Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
COGT Stock Forecast 2025-2026
$7.24
Current Price
$867.58M
Market Cap
Buy 8
Hold 3
Sell 0
Wall St Analyst Ratings
Distance to COGT Price Targets
+245.3%
To High Target of $25.00
+121.0%
To Median Target of $16.00
-3.3%
To Low Target of $7.00
COGT Price Momentum
+0.3%
1 Week Change
+45.4%
1 Month Change
-14.8%
1 Year Change
-7.2%
Year-to-Date Change
-42.6%
From 52W High of $12.61
+94.6%
From 52W Low of $3.72
📊 TOP ANALYST CALLS
Did COGT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Cogent Biosciences is one of their latest high-conviction picks.
Latest COGT Stock Price Targets & Analyst Predictions
Based on our analysis of 13 Wall Street analysts, COGT has a bullish consensus with a median price target of $16.00 (ranging from $7.00 to $25.00). The overall analyst rating is Strong Buy (8.2/10). Currently trading at $7.24, the median forecast implies a 121.0% upside. This outlook is supported by 8 Buy, 3 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Anupam Rama at JP Morgan, projecting a 245.3% upside. Conversely, the most conservative target is provided by Joel Beatty at Baird, suggesting a 3.3% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
COGT Analyst Ratings
8
Buy
3
Hold
0
Sell
COGT Price Target Range
Low
$7.00
Average
$16.00
High
$25.00
Current: $7.24
Latest COGT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for COGT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 17, 2025 | Needham | Ami Fadia | Hold | Reiterates | $0.00 |
| May 29, 2025 | JP Morgan | Anupam Rama | Overweight | Maintains | $25.00 |
| May 20, 2025 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $12.00 |
| May 7, 2025 | Baird | Joel Beatty | Neutral | Maintains | $7.00 |
| Mar 7, 2025 | Scotiabank | Louise Chen | Sector Outperform | Initiates | $17.00 |
| Feb 27, 2025 | Baird | Joel Beatty | Neutral | Maintains | $8.00 |
| Feb 26, 2025 | Needham | Ami Fadia | Hold | Reiterates | $0.00 |
| Jan 14, 2025 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $14.00 |
| Dec 11, 2024 | Needham | Ami Fadia | Hold | Downgrade | $15.00 |
| Dec 11, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $0.00 |
| Dec 10, 2024 | Needham | Ami Fadia | Buy | Reiterates | $15.00 |
| Dec 9, 2024 | Needham | Ami Fadia | Buy | Reiterates | $15.00 |
| Nov 14, 2024 | JP Morgan | Anupam Rama | Overweight | Maintains | $21.00 |
| Nov 13, 2024 | Needham | Ami Fadia | Buy | Maintains | $15.00 |
| Nov 4, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $17.00 |
| Oct 24, 2024 | Needham | Ami Fadia | Buy | Reiterates | $16.00 |
| Sep 24, 2024 | Citigroup | David Lebowitz | Buy | Maintains | $15.00 |
| Sep 5, 2024 | Baird | Joel Beatty | Neutral | Maintains | $10.00 |
| Sep 3, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $17.00 |
| Aug 7, 2024 | JP Morgan | Anupam Rama | Overweight | Maintains | $19.00 |
Cogent Biosciences Inc. (COGT) Competitors
The following stocks are similar to Cogent Biosciences based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
COGT
Cogent Biosciences
mkt cap
806.10M
Cogent Biosciences Inc. (COGT) Financial Data
Cogent Biosciences Inc. has a market capitalization of $867.58M with a P/E ratio of -3.7x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -84.0%.
Valuation Metrics
Market Cap
$867.58M
Enterprise Value
$747.18M
P/E Ratio
-3.7x
PEG Ratio
-3.3x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+29.8%
Current Ratio
5.1x
Debt/Equity
7.8x
ROE
-84.0%
ROA
-47.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Cogent Biosciences Inc. (COGT) Business Model
About Cogent Biosciences Inc.
What They Do
Develops precision therapies for genetic diseases.
Business Model
Cogent Biosciences operates as a clinical-stage biotechnology company focusing on developing targeted therapies for genetically driven diseases. The company generates revenue primarily through the advancement of its drug candidates, which are designed to address specific genetic abnormalities in oncology and rare disorders, ultimately leading to potential partnerships, licensing agreements, or product sales upon successful development and commercialization.
Additional Information
Cogent Biosciences is committed to precision medicine, emphasizing innovative solutions that aim to surpass the limitations of existing treatments. Its active development pipeline reflects a robust approach to meeting both rare and common clinical needs, thereby positioning itself as a significant player in the biotechnology sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
205
CEO
Mr. Andrew R. Robbins M.B.A.
Country
United States
IPO Year
2020
Website
www.cogentbio.comCogent Biosciences Inc. (COGT) Latest News & Analysis
Latest News
Quick Summary
The Company secured funding for growth, targeting the 2026 launch of bezuclastinib. It will report results from three pivotal trials this year, starting with SUMMIT in July.
Why It Matters
The facility's funding supports growth and the upcoming launch of bezuclastinib, while pivotal trial results could significantly impact stock valuation and market confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference
21 days ago
Quick Summary
No specific financial information or relevant details for investors were provided in the news excerpt regarding Waltham, Mass., and Boulder, Colo.
Why It Matters
The locations suggest potential collaboration or market expansion, impacting regional economic activity and investment opportunities in those areas.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Wall Street Analysts Believe Cogent Biosciences (COGT) Could Rally 224.37%: Here's is How to Trade
1 month ago
Quick Summary
Cogent Biosciences (COGT) has a consensus price target suggesting a 224.4% upside. Upward earnings estimate revisions may indicate potential near-term stock gains.
Why It Matters
Cogent Biosciences (COGT) shows significant upside potential, with earnings estimate revisions suggesting positive momentum, which could attract investors seeking growth opportunities.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Three key data readouts are scheduled for 2025: SUMMIT in July, APEX in the second half, and PEAK by year-end. The company ended Q1 2025 with $245.7 million in cash, funding operations into late 2026.
Why It Matters
Positive data readouts in 2025 could drive stock value, while strong cash reserves ensure operational stability, reducing bankruptcy risk and supporting continued research and development.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Waltham, Massachusetts, and Boulder, Colorado, are mentioned, but no specific financial news or events are provided in the excerpt for investor relevance.
Why It Matters
The mention of specific locations can indicate regional economic activity, potential market expansions, or partnerships, impacting company performance and stock valuations.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Cogent has had four abstracts accepted for poster presentation, showcasing its expertise in developing advanced therapeutics.
Why It Matters
Cogent's acceptance of four abstracts signals strong research capabilities and potential advancements in therapeutics, likely boosting investor confidence and interest in future growth.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About COGT Stock
What is Cogent Biosciences Inc.'s (COGT) stock forecast for 2025?
Based on our analysis of 13 Wall Street analysts, Cogent Biosciences Inc. (COGT) has a median price target of $16.00. The highest price target is $25.00 and the lowest is $7.00.
Is COGT stock a good investment in 2025?
According to current analyst ratings, COGT has 8 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $7.24. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for COGT stock?
Wall Street analysts predict COGT stock could reach $16.00 in the next 12 months. This represents a 121.0% increase from the current price of $7.24. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cogent Biosciences Inc.'s business model?
Cogent Biosciences operates as a clinical-stage biotechnology company focusing on developing targeted therapies for genetically driven diseases. The company generates revenue primarily through the advancement of its drug candidates, which are designed to address specific genetic abnormalities in oncology and rare disorders, ultimately leading to potential partnerships, licensing agreements, or product sales upon successful development and commercialization.
What is the highest forecasted price for COGT Cogent Biosciences Inc.?
The highest price target for COGT is $25.00 from Anupam Rama at JP Morgan, which represents a 245.3% increase from the current price of $7.24.
What is the lowest forecasted price for COGT Cogent Biosciences Inc.?
The lowest price target for COGT is $7.00 from Joel Beatty at Baird, which represents a -3.3% decrease from the current price of $7.24.
What is the overall COGT consensus from analysts for Cogent Biosciences Inc.?
The overall analyst consensus for COGT is bullish. Out of 13 Wall Street analysts, 8 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $16.00.
How accurate are COGT stock price projections?
Stock price projections, including those for Cogent Biosciences Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 19, 2025 2:43 AM UTC